TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: ASSURE WCD Clinical Evaluation - Detection and Safety Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females, age ≥ 18 years~2. Patients with an active Implantable Cardioverter Defibrillator (ICD)~3. Left Ventricular Ejection Fraction (LVEF) ≤ 40%, measured within the past year (12 months) by echocardiography, nuclear imaging (including MRI), or left ventricular angiography~4. Able and willing to provide written informed consent before undergoing any study-related procedures~Exclusion Criteria:~1. Any condition that by the judgement of the physician investigator precludes the subject's ability to comply with the study requirements, including cognitive and/or physical limitations that would prevent the subject from interacting with the device as intended~2. Any known skin allergy or sensitivity to the study garment materials that will be next to the skin~3. Any breached or compromised skin on the upper body that would be exacerbated by wearing the study garment~4. Work with or are frequently around equipment that produces high electromagnetic fields, for example magnetic resonance imaging devices, power supply facilities, or welding equipment~5. Any planned surgical or medical procedures during the participation period that would require the subject to remove the study device for more than 12 hours~6. Any planned air travel during the participation period~7. Pregnancy~8. Use of mechanical circulatory support, including but not limited to Left Ventricular Assist Device (LVAD) or Total Artificial Heart~9. Implanted Cardiac Resynchronization Therapy Defibrillator (CRT-D)~10. Simultaneous plan/prescription for Holter monitor, mobile cardiac outpatient telemetry (MCOT), Event Recorder, or in-hospital telemetry~11. Use of any electronic medical device that is worn on or near the body requires Sponsor approval, other than continuous positive airway pressure (CPAP), continuous blood glucose monitor, or pulse oximeter oxygen saturation (SpO2) monitor.~12. Under bust chest circumference greater than 52 inches or less than 28 inches~13. Current hospital inpatient

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Study Arm (Type: EXPERIMENTAL): Adult cardiac patients at risk for sudden cardiac arrest otherwise protected with an Implantable Cardioverter Defibrillator (ICD)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tolvaptan Open-label Pilot Efficacy, Tolerability, and Safety Study in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Prior participation in designated tolvaptan ADPKD studies (156-04-248, 156-04-249).~* Able to give Informed Consent.~Exclusion Criteria:~* Women who are breast feeding and females of childbearing potential who are not using acceptable contraceptive methods.~* In the opinion of the study investigator or sponsor may present a safety risk.~* Patients who are unlikely to adequately comply with study procedures.~* Patients who at Day 1 have an estimated glomerular filtration rate (GFR) below 30 mL/min or who anticipate renal-replacement therapy within one year of study entry.~* Patients having contraindications to magnetic resonance imaging (MRI) or gadolinium contrast will be eligible but will not be able to participate in MRI.~* Patients taking a diuretic within 1 week of enrollment or likely to need diuretic therapy prior to Month 2.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tolvaptan 45/15 mg/day orally for up to 4 years (Type: EXPERIMENTAL): Participants received tolvaptan 45 mg orally in the morning and 15 mg orally 8 hours later for up to 4 years.
- Tolvaptan 60/30 mg/day orally for up to 4 years (Type: EXPERIMENTAL): Participants received tolvaptan 60 mg orally in the morning and 30 mg orally 8 hours later for up to 4 years.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Timing of Indomethacin Administration for the Prevention of Post-ERCP Pancreatitis (PEP)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* All patients referred for ERCP at the University of Alberta~* Age greater than 18 years~* Ability to provide written informed consent~Exclusion Criteria:~* Acute pancreatitis~* Active peptic ulcer disease~* Rectal disease~* Aspirin-induced asthma~* Nonsteroidal anti-inflammatory drug (NSAIDs) induced hypersensitivity~* Pregnancy~* Breast feeding~* Creatinine clearance \< 30 ml/min

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Rectal Indomethacin pre-ERCP (Type: ACTIVE_COMPARATOR): Patients will receive rectal indomethacin 100mg 30 minutes before procedure (ERCP).
- Rectal Indomethacin post-ERCP (Type: ACTIVE_COMPARATOR): Patients will receive rectal indomethacin 100mg immediately after procedure (ERCP)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Males or females, 18 years of age or older with active rheumatoid arthritis; Or male and female healthy volunteers 18 years of age and older~Exclusion Criteria:~* Pregnant or lactating women~* Clinically significant systemic disease (other than RA for RA arm)~* Use of lipid-regulating agents

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- CP-690,550 (tasocitinib) 10 mg twice daily (BID) (Type: EXPERIMENTAL): None
- Healthy Volunteers (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Impact of Nursing Interventions on Adherence to Treatment With Anti-tuberculosis Drugs in Children and Adolescents

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* In both phases, all children and adolescents (aged \<18 years) starting anti-TB treatment due to close contact with a TB patient (primary chemoprophylaxis), Latent Tuberculosis Infectious (LTBI) or Tuberculosis (TB) disease were eligible to participate in the study.~Exclusion Criteria:~* Referral from another center after anti-TB treatment had already begun~* Patients with other chronic diseases requiring hospital follow-up and/or other chronic therapies~* Known poor previous adherence to anti-TB treatment (if treatment was repeated or restarted)~* A significant language barrier that prevented the child or his/her relatives from properly understanding the nature of the study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Phase 1, Retrospective (Type: NO_INTERVENTION): Routine outpatient follow-up visits were scheduled as follows: (a) in patients receiving primary chemoprophylaxis or Latent Tuberculosis Infection (LTBI) treatment: baseline visit, and 2 weeks and 3 months later (end of treatment in most cases); (b) in patients treated for Tuberculosis disease: baseline visit, 2 weeks later and on a monthly basis thereafter.
- Phase 2, Prospective (Type: EXPERIMENTAL): Four nurse-led interventions were implemented after Phase 1:~* Intervention 1: at baseline visit, the parents or carers of the children, were given a leaflet in the mother tongue. This leaflet was available in 10 different languages: Spanish and Catalan (the two official languages of the country), English, French, German, Russian, Romanian, Chinese, Urdu and Arabic.~* Intervention 2: a follow-up open telephone call was made 7-10 days after the baseline visit and whenever the patient failed to attend the scheduled visits.~* Intervention 3: the Eidus-Hamilton test was performed twice, 2 weeks after the baseline visit and at the end of treatment. To prevent patients from only taking their medication occasionally, directly before their visits, they were not informed of the purpose of the urine test.~* Intervention 4: a written questionnaire about adherence to anti-TB treatment on all the follow-up visits.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study to Investigate Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy in Asthma Patients Across Asia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Provision of signed informed consent~* Asthma diagnosis at least 6 months before visit 1 of study~* Patients who have reversible airway obstruction continuous asthma treatment except Symbicort at least within 4 weeks before visit 1 of study~Exclusion Criteria:~* Known or suspected allergy to active ingredients of study medication or excipients~* Use of oral, rectal or parenteral glucocorticosteroids 30 days before visit 1 of study~* Smoking, current or previous with a smoking history of ≥ 10 pack years

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Symbicort Turbuhaler 160/4.5 µg delivered dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of 4-aminopyridine on Cognitive Performance and Motor Function of Patients With Multiple Sclerosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria: Patients with multiple sclerosis (MS) are eligible for the study if they meet the following criteria:~1. Relapsing recurrent MS with an evolution of at last 6 months before the study began.~2. Both males and females, aged 20 - 65 years~3. Neurologic Expanded Disability Status Scale (EDSS) 3 - 7~4. Who are in first-line immunomodulatory therapy and have a stable disease~5. No more than one outbreak per year.~6. The absence of antiepileptic antecedent and electroencephalogram without epileptic activity.~7. For females: postmenopausal or surgically sterile, or using an acceptable method of birth control~Exclusion Criteria:~1. History of cardiovascular disease (syncope, arrhythmia, or myocardial infarction within the last two years), systolic blood pressure greater than 150 or less than 70 mm Hg, diastolic blood pressure greater than 110 or less than 50 mm Hg, or heart rate greater than 110 or less than 50 beats/minute; impaired hepatic function (total hepatic enzyme or bilirubin levels greater than 2 times the upper limits of normal) or impaired renal function (creatinine level greater than 2 times the upper limits of normal) less than 6 months before the study~2. Known allergy to pyridine-containing drugs~3. Neurologic, degenerative, or psychiatric disorders that would impair the patient's ability to complete the protocol~4. Any illness or abnormality that would jeopardize patient safety or interfere with the conduct of the study~5. History of substance abuse~6. Inability to discontinue excluded concomitant drug therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- 4-aminopyridine treatment (Type: ACTIVE_COMPARATOR): 4-aminopyridine is given as gelatin capsules containing 4-aminopyridine 10 mg and microcrystalline cellulose as the excipient. Each patient will take two capsules every 8 hours after meals, for a total of 6 capsules/day. The 4-aminopyridine dosage will increase 10 mg/4 weeks by substitution of placebo instead of 4-aminopyridine capsules; such that patients will receive from 40 to 60 mg. distribute in 6capsules/day throughout the study.
- Placebo (Type: PLACEBO_COMPARATOR): Patients randomized to the placebo sequence will receive placebo for 20 weeks after the run-in period. They will be blinded to the fact that they are taking placebo, and capsules will be identical in appearance to the intervention capsules.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Misoprostol Versus Oxytocin for Prevention of Post Partum Hemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* were women with singleton pregnancy~* with cephalic presentation~* who had NVD spontaneously or by induction~Exclusion Criteria:~* placenta previa~* placental detachment~* coagulation problems~* previous CS~* macrosomia~* Polyhydramnios~* and uncontrolled asthma

- Gender: FEMALE
- Minimum Age: 10 Years
- Maximum Age: 50 Years
- Healthy Volunteers: t

Study Arms:
- Misoprostol (Type: EXPERIMENTAL): 400µg oral misoprostol
- Oxytocin (Type: ACTIVE_COMPARATOR): 20 IU oxytocin

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ORthopaedic Trauma Anemia With Conservative Versus Liberal Transfusion

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Trauma patients admitted to participating hospital with any Orthopaedic injury who have been determined to be stable by the Trauma Service (General Surgery) and are no longer within the resuscitation phase of initial treatment. This is defined as a normal urine output (greater than 0.5 ml/kg/hr) and a systolic blood pressure greater than 90 mmHg for greater than 6 hours without fluid bolus or transfusion during that time~* Age 18-50~* Hemoglobin less than 9 g/dL or expected drop below 9 g/dL with planned surgery~Exclusion Criteria:~* Pregnant ( urine pregnancy test will be done as standard of care)~* Prisoner~* Head injury (Glasgow Coma Scale less than 8 over 48 hours from presentation)~* Known cardiac (coronary artery disease, atrial fibrillation, stent placement, congestive heart failure), renal (acute or chronic renal insufficiency or failure, defined as having Serum Creatinine \>1.2 at time of enrollment), liver (Childs C cirrhosis) or pulmonary disease (chronic obstructive pulmonary disease, abnormal pulmonary function tests or history of poor pulmonary function from any cause including acute traumatic conditions such as ARDS)~* Unlikely to follow up in the surgeon's estimation~* Sickle Cell Anemia~* History of cancer~* Preexisting weakness, paresthesias, deformities, or other conditions which might affect functional outcome in the surgeon's opinion~* Spinal cord injury~* Patients with burns expected to require operative treatment~* COVID positive

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Liberal (Type: OTHER): Blood and blood products for transfusion. Transfusion will be done to keep Hgb \>7 g/dL.
- Conservative (Type: OTHER): Blood and blood products for transfusion. Transfusion will be done to keep Hgb \> 5.5 g/dL.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Retrospective Observational Study to Assess the Impact of Co-morbidities on Treatment Response in Inflammatory Bowel Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: RETROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult participants (aged ≥18).~* Were diagnosed with UC or CD according to the World Gastroenterology Organization Practice Guidelines for the Diagnosis and Management of inflammatory bowel disease (IBD) in 2010.~* Who were naive to biologics that started treatment with biologics between June 2011 and June 2013.~* Participants in whom biological treatment was prescribed according to clinical practice.~* Who gave written informed consent.~Exclusion Criteria:~* Were participating in a clinical trial during the study reference period.~* Participant that, according to investigator's criteria was not capable to understand and fill in the study questionnaires or to give written informed consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cohort 1: Crohn's Disease (Type: None): Participants with Crohn's disease who received biological treatment between June 2011 and June 2013.
- Cohort 2: Ulcerative Colitis (Type: None): Participants with ulcerative colitis who received biological treatment between June 2011 and June 2013.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Sublingual Misoprostol Versus Standard Surgical Care for the Treatment of Incomplete Abortion in Nigeria

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* no contraindications to misoprostol~* uterine size was not larger than 12 weeks~* there were no signs of severe infection~* haemodynamically stable~* in general good health~* willing to provide contact information~Exclusion Criteria:~* an IUD in place~* ectopic pregnancy~* aged below 18 years and had no accompanying adult to provide informed consent

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Misoprostol (Type: ACTIVE_COMPARATOR): 400 mcg of sublingual misoprostol in one dose
- Manual vacuum aspiration (MVA) (Type: ACTIVE_COMPARATOR): Standard surgical treatment (MVA)

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Ledipasvir/Sofosbuvir (LDV/SOF) Fixed Dose Combination Tablet With Ribavirin for 12 Weeks in Treatment-naive Adults With Chronic HCV Genotype 3 Infection

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Key Inclusion Criteria:~* Chronic genotype 3 HCV infection~* HCV treatment-naive~* HCV RNA \> 10,000 IU/mL at screening~* Absence of cirrhosis or compensated cirrhosis~* Screening laboratory values within defined thresholds~* Use of two effective contraception methods if female of childbearing potential or sexually active male~Key Exclusion Criteria:~* Pregnant or nursing female or male with pregnant female partner~* Coinfection with HIV or hepatitis B virus (HBV)~* Current or prior history of clinical hepatic decompensation~* Chronic use of systemic immunosuppressive agents~* History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment, or compliance with the protocol~Note: Other protocol defined Inclusion/Exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LDV/SOF+RBV (Type: EXPERIMENTAL): LDV/SOF FDC plus RBV for 12 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparative Study of NXL104/Ceftazidime Versus Comparator in Adults With Complicated Urinary Tract Infections

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute pyelonephritis or other complicated urinary tract infection due to gram negative pathogens~Exclusion Criteria:~* ileal loops or vesicoureteral reflux~* complete obstruction of any portion of urinary tract, perinephric or intrarenal abscess.~* fungal urinary tract infection~* permanent indirect catheter or nephrostomy unless removed within 48 hours of study entry~* history hypersensitivity to study medication

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): NXL/104 ceftazidime
- 2 (Type: ACTIVE_COMPARATOR): comparator 4 x daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete